Florence Lorget

Florence was appointed Chief Development Sciences Officer of SparingVision.

From 2018 to 2020, Florence was the Senior Director for Nonclinical Safety Evaluation at Sangamo Therapeutics, a genomic medicine company, where she oversaw the pharmacology, toxicology and PK activities for a large portfolio of gene editing, gene regulation and gene therapy programs in various therapeutic areas. Prior to Sangamo, from 2013 to 2018, she was a Senior Scientist in the Safety Assessment department at Genentech. There, she was the Toxicology Therapeutic Area Lead for Ophthalmology. She also led the Ocular Platform Team, a cross-functional team focusing on the early development of long acting delivery strategies. From 2007 to 2013, Florence was a Senior Pharmacologist/Toxicologist at BioMarin where she was a key contributor to the nonclinical development of Vimizim®, an enzyme replacement therapy for Morquio syndrome, a rare lysosomal storage disorder, and of Vosoritide, a C-type natriuretic peptide for the treatment of Achondroplasia. Florence started her industry career at Amgen working on the Avimer™ technology. Florence obtained a Master in Bioengineering from the University of Technology of Compiegne (France). She received a Pharm D and a PhD in Cellular and Molecular Biology from the University of Picardie- Jules Verne (France).

Her postdoctoral work at the Nestle Research Center (Lausanne, Switzerland) and at the University of California San Francisco (UCSF) focused on osteoclast biology and the role of TGF-b on mesenchymal stem cell biology, respectively. Dr. Lorget has been a Diplomate of the American Board of Toxicology since 2014.

Florence is based in San Francisco, USA